$3.55 Billion is the total value of BB BIOTECH AG's 30 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IONS | New | Ionis Pharmaceuticals Inc. | $404,393,000 | – | 6,529,838 | +100.0% | 11.39% | – |
| SAGE | New | Sage Therapeutics, Inc. | $41,315,000 | – | 708,663 | +100.0% | 1.16% | – |
| CDTX | New | Cidara Therapeutics, Inc. | $8,008,000 | – | 466,679 | +100.0% | 0.23% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Biotech Focus N.V. #1
- Biotech Invest N.V. #2
- Biotech Target N.V. #3
- Biotech Growth N.V. #4
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Celgene Corporation | 24 | Q1 2019 | 18.3% |
| Incyte Corporation | 24 | Q1 2019 | 15.3% |
| Gilead Sciences, Inc. | 24 | Q1 2019 | 14.2% |
| Vertex Pharmaceuticals Incorporated | 24 | Q1 2019 | 8.1% |
| Alexion Pharmaceuticals, Inc. | 24 | Q1 2019 | 5.7% |
| Halozyme Therapeutics, Inc. | 24 | Q1 2019 | 4.9% |
| Alnylam Pharmaceuticals, Inc. | 24 | Q1 2019 | 3.8% |
| Neurocrine Biosciences, Inc. | 23 | Q1 2019 | 10.3% |
| Regeneron Pharmaceuticals, Inc. | 22 | Q4 2018 | 3.5% |
| Achillion Pharmaceuticals, Inc. | 22 | Q3 2018 | 1.0% |
View BB BIOTECH AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Kezar Life Sciences, Inc. | February 14, 2023 | 3,000,000 | 4.4% |
| Mersana Therapeutics, Inc. | February 14, 2023 | 4,066,200 | 4.1% |
| Molecular Templates, Inc. | February 14, 2023 | 11 | 19.9% |
| Myovant Sciences Ltd. | February 14, 2023 | 5,872,639 | 6.0% |
| Scholar Rock Holding Corp | February 14, 2023 | 2,132,725 | 4.1% |
| Radius Health, Inc.Sold out | August 30, 2022 | 0 | 0.0% |
| Cidara Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| Voyager Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| HALOZYME THERAPEUTICS, INC. | February 12, 2021 | 3,970,000 | 2.9% |
| Intra-Cellular Therapies, Inc. | February 12, 2021 | 3,538,419 | 4.4% |
View BB BIOTECH AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 4 | 2024-04-04 |
| 13F-NT | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View BB BIOTECH AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.